Role of Circulating Tumor DNA in Colorectal Cancer

Overview

Journal Methods Mol Biol

Specialty Molecular Biology

Date 2023 Jul 14

PMID 37450122

Authors

Haotian Li

Sheng Lu

Zidong Zhou

Xiaocheng Zhu

Yong Shao

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer (CRC) is a very common gastrointestinal tumor, ranking second in the global cause of cancer death. Because of the invasive nature of biopsy and cannot reflect the heterogeneity of tumor or monitor the dynamic progress of tumor, it is necessary to induce a novel noninvasive method to improve the current treatment strategies of colorectal cancer. Among all the components of liquid biopsy, circulating tumor DNA (ctDNA) may have the best future. CtDNA maintains the same genomic characteristics as those in matched tumor tissues, so it allows quantitative evaluation and analysis of mutation load in body fluid. Furthermore, because the half-life of ctDNA is from 16 min to several hours in circulation, the circulating ctDNA can be measured repeatedly within a certain period to monitor the response of CRC to treatment, the occurrence of drug resistance, and the diagnosis of recurrence.

References

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

Gu C, Shi X, Dai C, Shen F, Rocco G, Chen J . RNA mA Modification in Cancers: Molecular Mechanisms and Potential Clinical Applications. Innovation (Camb). 2021; 1(3):100066. PMC: 8454620. DOI: 10.1016/j.xinn.2020.100066. View

Douaiher J, Ravipati A, Grams B, Chowdhury S, Alatise O, Are C . Colorectal cancer-global burden, trends, and geographical variations. J Surg Oncol. 2017; 115(5):619-630. DOI: 10.1002/jso.24578. View

Brenner H, Kloor M, Pox C . Colorectal cancer. Lancet. 2013; 383(9927):1490-1502. DOI: 10.1016/S0140-6736(13)61649-9. View

Ludwig J, Weinstein J . Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer. 2005; 5(11):845-56. DOI: 10.1038/nrc1739. View

Gu C, Chen C . Methylation in Lung Cancer: A Brief Review. Methods Mol Biol. 2020; 2204:91-97. DOI: 10.1007/978-1-0716-0904-0_8. View

Stroun M, Lyautey J, LEDERREY C, Anker P . About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta. 2001; 313(1-2):139-42. DOI: 10.1016/s0009-8981(01)00665-9. View

Mandel P, Metais P . Nuclear Acids In Human Blood Plasma. C R Seances Soc Biol Fil. 1948; 142(3-4):241-3. View

Leon S, Shapiro B, SKLAROFF D, Yaros M . Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977; 37(3):646-50. View

10.

Stroun M, Anker P, Maurice P, Lyautey J, LEDERREY C, Beljanski M . Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology. 1989; 46(5):318-22. DOI: 10.1159/000226740. View

11.

Wang J, Hsieh J, Chang M, Huang T, Chen F, Cheng T . Molecular detection of APC, K- ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers. World J Surg. 2004; 28(7):721-6. DOI: 10.1007/s00268-004-7366-8. View

12.

Shaw J, Smith B, Walsh T, Johnson S, Primrose L, Slade M . Microsatellite alterations plasma DNA of primary breast cancer patients. Clin Cancer Res. 2000; 6(3):1119-24. View

13.

Fujiwara K, Fujimoto N, Tabata M, Nishii K, Matsuo K, Hotta K . Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin Cancer Res. 2005; 11(3):1219-25. View

14.

Filho E, Simon D, Ikuta N, Klovan C, Dannebrock F, Oliveira C . Elevated cell-free plasma DNA level as an independent predictor of mortality in patients with severe traumatic brain injury. J Neurotrauma. 2014; 31(19):1639-46. PMC: 4171115. DOI: 10.1089/neu.2013.3178. View

15.

Tsai N, Lin T, Chen S, Chang W, Wang H, Yang T . The value of serial plasma nuclear and mitochondrial DNA levels in patients with acute ischemic stroke. Clin Chim Acta. 2010; 412(5-6):476-9. DOI: 10.1016/j.cca.2010.11.036. View

16.

De Vlaminck I, Valantine H, Snyder T, Strehl C, Cohen G, Luikart H . Circulating cell-free DNA enables noninvasive diagnosis of heart transplant rejection. Sci Transl Med. 2014; 6(241):241ra77. PMC: 4326260. DOI: 10.1126/scitranslmed.3007803. View

17.

De Vlaminck I, Martin L, Kertesz M, Patel K, Kowarsky M, Strehl C . Noninvasive monitoring of infection and rejection after lung transplantation. Proc Natl Acad Sci U S A. 2015; 112(43):13336-41. PMC: 4629384. DOI: 10.1073/pnas.1517494112. View

18.

Diehl F, Schmidt K, Choti M, Romans K, Goodman S, Li M . Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008; 14(9):985-90. PMC: 2820391. DOI: 10.1038/nm.1789. View

19.

Lo Y, Zhang J, Leung T, Lau T, Chang A, Hjelm N . Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet. 1999; 64(1):218-24. PMC: 1377720. DOI: 10.1086/302205. View

20.

Schwarzenbach H, Stoehlmacher J, Pantel K, Goekkurt E . Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer. Ann N Y Acad Sci. 2008; 1137:190-6. DOI: 10.1196/annals.1448.025. View